| Literature DB >> 28267084 |
Kenichiro Kobayashi1, Takako Yoshioka, Jun Miyauchi, Atsuko Nakazawa, Shigeaki Yamazaki, Hiromi Ono, Michiko Tatsuno, Kenta Iijima, Chiaki Takahashi, Yoko Okada, Kenji Teranishi, Takaaki Matsunaga, Chieko Matsushima, Mayo Inagaki, Minoru Suehiro, Saori Suehiro, Masahiko Nishitani, Hirohito Kubota, Jun Iio, Yoshinobu Nishida, Tetsuo Katayama, Narito Takada, Kentaro Watanabe, Tetsuro Yamamoto, Ryoji Yasumizu, Kentaro Matsuoka, Kentaro Ohki, Nobutaka Kiyokawa, Toshiro Maihara, Ikuya Usami.
Abstract
Liver fibrosis is one of the common complications of transient myeloproliferative disorder (TMD) in Down syndrome (DS), but the exact molecular pathogenesis is largely unknown. We herein report a neonate of DS with liver fibrosis associated with TMD, in which we performed the serial profibrogenic cytokines analyses. We found the active monocyte chemoattractant protein-1 expression in the affected liver tissue and also found that both serum and urinary monocyte chemoattractant protein-1 concentrations are noninvasive biomarkers of liver fibrosis. We also showed a prospective of the future anticytokine therapy with herbal medicine for the liver fibrosis associated with TMD in DS.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28267084 DOI： 10.1097/MPH.0000000000000809
Source DB: PubMed Journal: J Pediatr Hematol Oncol ISSN： 1077-4114 Impact factor: 1.289